Evidence map›Paper›PMID 28349233›Full record

Trial reportDigestive diseases and sciences2017

Low-Dose Cannabidiol Is Safe but Not Effective in the Treatment for Crohn's Disease, a Randomized Controlled Trial.

Timna Naftali, Refael Mechulam, Amir Marii, Gila Gabay, Asaf Stein, Miriam Bronshtain, Ido Laish, Fabiana Benjaminov, Fred M Konikoff

Registry-linked trialAbstract readRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in Digestive diseases and sciences, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01037322 (Use of Cannabidiol for the Treatment of Inflammatory Bowel Disease), which is not on this map. Cited by 102 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
102citing papers in PubMed, 7 pooled it
15.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01037322 phase1 / phase2completednot on this map

Use of Cannabidiol for the Treatment of Inflammatory Bowel Disease

TypeinterventionalSponsorMeir Medical CenterRan2010 to 2012Enrolled20ConditionsCrohn's Disease, Ulcerative ColitisArmscannabidiol, placebo in drops
3 · Its place in the literature

Who cites it

102 citing papers in PubMed, 7 syntheses or guidelines pooled it, 211 citations in OpenAlex.

  1. Pooled it
  2. The impact of cannabis on immune checkpoint inhibitor therapy: a systematic review of immunomodulatory effects of cannabis in patients with and without cancer.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025
    Pooled it
  3. Pooled it
  4. Pooled it
  5. A systematic review of cannabidiol dosing in clinical populations.British journal of clinical pharmacology · 2019
    Pooled it
  6. Cannabis for the treatment of Crohn's disease.The Cochrane database of systematic reviews · 2018
    Pooled it
  7. Cannabinoids in Pain Management and Palliative Medicine.Deutsches Arzteblatt international · 2017
    Pooled it
  8. Effects and safety of a CBD-richFrontiers in pharmacology · 2025
    Trial
  9. Trial
  10. Trial
  11. Trial
  12. Article
  13. Review
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Review
  20. Review

42 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Timna NaftaliDepartment of Gastroenterology, Meir Medical Center, 59 Tchernihovsky st., 4441002, Kfar Saba, Israel. Timna.naftali@clalit.org.il.ORCID 0000-0002-8931-6524
Refael MechulamSchool of Pharmacology, Hadassa Medical School, Hebrew University of Jerusalem, Jerusalem, Israel.
Amir MariiHilel Yafe Medical Center, Hshalom st., 38100, Hadera, Israel.
Gila GabayDepartment of Gastroenterology, Meir Medical Center, 59 Tchernihovsky st., 4441002, Kfar Saba, Israel.
Asaf SteinDepartment of Gastroenterology, Meir Medical Center, 59 Tchernihovsky st., 4441002, Kfar Saba, Israel.
Miriam BronshtainDepartment of Gastroenterology, Meir Medical Center, 59 Tchernihovsky st., 4441002, Kfar Saba, Israel.
Ido LaishDepartment of Gastroenterology, Meir Medical Center, 59 Tchernihovsky st., 4441002, Kfar Saba, Israel.
Fabiana BenjaminovDepartment of Gastroenterology, Meir Medical Center, 59 Tchernihovsky st., 4441002, Kfar Saba, Israel.
Fred M KonikoffDepartment of Gastroenterology, Meir Medical Center, 59 Tchernihovsky st., 4441002, Kfar Saba, Israel.
Tel Aviv University · ILHebrew University of Jerusalem · ILHillel Yaffe Medical Center · IL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCannabidiol (CBD) is an anti-inflammatory cannabinoid shown to be beneficial in a mouse model of IBD. Lacking any central effect, cannabidiol is an attractive option for treating inflammatory diseases.

aimTo assess the effects of cannabidiol on Crohn's disease in a randomized placebo-controlled trial. PATIENTS AND

methodsTwenty patients aged 18-75 years with a Crohn's disease activity index (CDAI) >200 were randomized to receive oral (10 mg) CBD or placebo twice daily. Patients did not respond to standard treatment with steroids (11 patients), thiopurines (14), or TNF antagonists (11). Disease activity and laboratory parameters were assessed during 8 weeks of treatment and 2 weeks thereafter. Other medical treatment remained unchanged.

resultsOf 20 patients recruited 19 completed the study. Their mean age was 39 ± 15, and 11 were males. The average CDAI before cannabidiol consumption was 337 ± 108 and 308 ± 96 (p = NS) in the CBD and placebo groups, respectively. After 8 weeks of treatment, the index was 220 ± 122 and 216 ± 121 in the CBD and placebo groups, respectively (p = NS). Hemoglobin, albumin, and kidney and liver function tests remained unchanged. No side effects were observed.

conclusionIn this study of moderately active Crohn's disease, CBD was safe but had no beneficial effects. This could be due to lack of effect of CBD on Crohn's disease, but could also be due to the small dose of CBD, the small number of patients in the study, or the lack of the necessary synergism with other cannabinoids. Further investigation is warranted. CLINICALTRIALS.GOV: NCT01037322.

Indexed as

CannabisPhytotherapyAdolescentAdultAgedCannabidiolCrohn DiseaseFemaleHumansMaleMiddle AgedPlant ExtractsSeverity of Illness IndexTreatment FailureYoung AdultCannabidiolPlant ExtractsCannabidiolCannabisCrohn’s diseaseInflammatory bowel disease

Identifiers

PMID28349233
OpenAlexW2603876369

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.